摘要
目的 :研究茶碱控释片 (优喘平 )在睡眠呼吸暂停 (SAS)病人中的药物动力学。方法 :采用荧光偏振免疫法 ,测定 6例SAS病人首次口服优喘平 6 0 0mg后 48h内的血清茶碱浓度。结果 :血清中茶碱浓度在 12h左右达峰 ( 7.2 5 μg·ml-1) ,消除半衰期为 11.5h ,分布容积为 44 .49L ,总体清除率为 2 .6 1L·h-1,由此计算出达到有效治疗浓度 ( 10 μg·ml-1)所需的优喘平平均日剂量为 733mg。优喘平服药 3d达稳态时的峰谷浓度波动系数为2 4.31%。结论 :优喘平在SAS病人中口服给药后的药动学特征符合控释制剂要求 ,血药浓度波动较小 ,稳态时可达有效治疗浓度 ,为SAS病人安全有效用药提供了依据。
OBJECTIVE:To evaluate the pharmacokinetics of a sustained release theophylline (Protheo,Schering Plough,USA) in 6 patients with sleep apnea syndrome (SAS).METHODS:A 48 h bolld collection was done after patient received Protheo at a dose of 600 mg. The serum concentrations of theophylline were measured by a fluorescence polarization immunoassay.RESULTS:Serum peak level reached at about 12 h with a average value of 7.25 μg·ml -1 .Average elimination half life was 11.55 h.Average total body clearance was 2.61 L·h -1 .Steady state level was attained after three day's dosing.The fluctuation percentage of peak trough levels of theophylline was 24.31 %。CONCLUSIONS:The results suggest that Protheo meets the requirement of sustained release preparation.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2000年第1期13-14,共2页
Chinese Journal of Hospital Pharmacy
关键词
睡眠性
呼吸暂停
茶碱
控释片
药物动力学
sustained release
theophylline
pharmacokinetics
sleep apnea syndrome
